Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Bavarian Nordic

The emergence of a new more deadly strain of the mpox virus has led the World Health Organization to declare a global public health emergency and has created a surge in demand for vaccines and therapies. The company best placed to meet this urgent need is Bavarian Nordic, which manufactures Jynneos, the only mpox vaccine approved in both the US and EU.

The company’s share price has shot up by more than a third over the last week as fears about the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Market Access